Pharmaceuticals
Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
Published in Blood Weekly, March 12th, 2009
Nostrum Pharmaceuticals, LLC ("Nostrum"), a privately-held company based in Edison, New Jersey, announced that it has obtained a worldwide license to develop and commercialize Caerulomycin A, and its proprietary derivatives and analogues ("Caerulomycin") for their novel indication of immunosuppression. The license was obtained from Institute of Microbial Technology ("IMTECH"), Chandigarh, India, one of India's preeminent research institutes, governed by the national government's Council of Scientific and Industrial Research ("CSIR").
Nostrum's President and founder, Dr. Nirmal Mulye, Ph.D., expressed his appreciation for the continued efforts by IMTECH and Nostrum's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-03-12)
More Articles from Blood Weekly
- Harvard School of Public Health
Diets that reduce calories lead to weight loss, regardless of carbohydrate, protein or fat content - Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Reports Fourth Quarter and 2008 Financial Results - Biopsy
Research from A.M. Alkhunaizi et al broadens understanding of biopsy - Coagulation
Scientists at University of Amsterdam describe research in coagulation - Enzyme Research
Reports on enzyme research findings from Yale University, Medical Department provide new insights - Gastroenterology
Findings in gastroenterology reported from National Chung-Hsing University - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
